Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

A phase I clinical study of intratumorally administered VB4-845, an anti-epithelial cell adhesion molecule recombinant fusion protein, in patients with squamous cell carcinoma of the head and neck.

MacDonald GC, Rasamoelisolo M, Entwistle J, Cuthbert W, Kowalski M, Spearman MA, Glover N.

Med Oncol. 2009;26(3):257-64. doi: 10.1007/s12032-008-9111-x. Epub 2008 Oct 28.

PMID:
19016010
2.

A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck.

MacDonald GC, Rasamoelisolo M, Entwistle J, Cizeau J, Bosc D, Cuthbert W, Kowalski M, Spearman M, Glover N.

Drug Des Devel Ther. 2009 Feb 6;2:105-14.

3.

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald GC.

Drug Des Devel Ther. 2010 Nov 15;4:313-20. doi: 10.2147/DDDT.S14071.

4.

VB4-845, a conjugated recombinant antibody and immunotoxin for head and neck cancer and bladder cancer.

Biggers K, Scheinfeld N.

Curr Opin Mol Ther. 2008 Apr;10(2):176-86.

PMID:
18386230
5.

The role of intratumoral therapy with cisplatin/epinephrine injectable gel in the management of advanced squamous cell carcinoma of the head and neck.

Wenig BL, Werner JA, Castro DJ, Sridhar KS, Garewal HS, Kehrl W, Pluzanska A, Arndt O, Costantino PD, Mills GM, Dunphy FR 2nd, Orenberg EK, Leavitt RD.

Arch Otolaryngol Head Neck Surg. 2002 Aug;128(8):880-5.

PMID:
12162764
6.

Intratumoral cisplatin/epinephrine gel in advanced head and neck cancer: a multicenter, randomized, double-blind, phase III study in North America.

Castro DJ, Sridhar KS, Garewal HS, Mills GM, Wenig BL, Dunphy FR 2nd, Costantino PD, Leavitt RD, Stewart ME, Orenberg EK.

Head Neck. 2003 Sep;25(9):717-31.

PMID:
12953307
7.
8.

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck.

Machiels JP, Kaminsky MC, Keller U, Brümmendorf TH, Goddemeier T, Forssmann U, Delord JP.

Invest New Drugs. 2013 Oct;31(5):1207-16. doi: 10.1007/s10637-013-9933-z. Epub 2013 Feb 10.

PMID:
23397499
9.

Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neck.

Abele R, Kaplan E, Grossenbacher R, Schmid HJ, Cavalli F.

Eur J Cancer Clin Oncol. 1984 Mar;20(3):333-6.

PMID:
6231185
10.

Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck. A phase II Southwest Oncology Group study.

Smith RE, Lew D, Rodriguez GI, Taylor SA, Schuller D, Ensley JF.

Invest New Drugs. 1996;14(4):403-7.

PMID:
9157077
11.
12.

Docetaxel and cisplatin: an active regimen in patients with locally advanced, recurrent or metastatic squamous cell carcinoma of the head and neck. Results of a phase II study of the EORTC Early Clinical Studies Group.

Schöffski P, Catimel G, Planting AS, Droz JP, Verweij J, Schrijvers D, Gras L, Schrijvers A, Wanders J, Hanauske AR.

Ann Oncol. 1999 Jan;10(1):119-22.

PMID:
10076732
13.

A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.

Fury MG, Lee NY, Sherman E, Ho AL, Rao S, Heguy A, Shen R, Korte S, Lisa D, Ganly I, Patel S, Wong RJ, Shaha A, Shah J, Haque S, Katabi N, Pfister DG.

Int J Radiat Oncol Biol Phys. 2013 Nov 1;87(3):479-86. doi: 10.1016/j.ijrobp.2013.06.2043.

PMID:
24074921
14.

Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I-II study.

Recchia F, Lalli A, Lombardo M, De Filippis S, Saggio G, Fabbri F, Rosselli M, Capomolla E, Rea S.

Cancer. 2001 Aug 15;92(4):814-21.

PMID:
11550152
15.

A phase III placebo-controlled study in advanced head and neck cancer using intratumoural cisplatin/epinephrine gel.

Werner JA, Kehrl W, Pluzanska A, Arndt O, Lavery KM, Glaholm J, Dietz A, Dyckhoff G, Maune S, Stewart ME, Orenberg EK, Leavitt RD.

Br J Cancer. 2002 Oct 21;87(9):938-44.

16.
17.

Phase II trial of N-methylformamide in advanced head and neck cancer.

Vogel WC, Forastiere AA, Natale RB, Takasugi BJ, Schnur G.

Invest New Drugs. 1987;5(2):203-6.

18.

[Recombinant adenovirus-p53 gene therapy combined with radiotherapy for head and neck squamous-cell carcinoma].

Zhang SW, Xiao SW, Liu CQ, Sun Y, Su X, Li DM, Xu G, Zhu GY, Xu B.

Zhonghua Zhong Liu Za Zhi. 2005 Jul;27(7):426-8. Chinese.

PMID:
16188130
19.

Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.

Thomas SM, Ogagan MJ, Freilino ML, Strychor S, Walsh DR, Gooding WE, Grandis JR, Zamboni WC.

Mol Pharmacol. 2008 Mar;73(3):627-38. Epub 2007 Nov 19.

20.

Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer.

Kawakami K, Kawakami M, Joshi BH, Puri RK.

Cancer Res. 2001 Aug 15;61(16):6194-200.

Supplemental Content

Support Center